Derik De Bruin
Stock Analyst at B of A Securities
(4.71)
# 173
Out of 4,667 analysts
197
Total ratings
69.05%
Success rate
16.41%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Downgrades: Neutral | $250 → $215 | $187.90 | +14.42% | 4 | Oct 2, 2024 | |
| TMO Thermo Fisher | Maintains: Buy | $600 → $675 | $512.84 | +31.62% | 17 | Sep 16, 2024 | |
| PAHC Phibro Animal Health | Maintains: Underperform | $13 → $15 | $23.39 | -35.87% | 4 | Aug 30, 2024 | |
| A Agilent Technologies | Maintains: Neutral | $140 → $147 | $128.57 | +14.33% | 30 | Aug 22, 2024 | |
| FTRE Fortrea Holdings | Maintains: Underperform | $26 → $21 | $19.15 | +9.66% | 5 | Aug 13, 2024 | |
| LH Labcorp Holdings | Maintains: Buy | $240 → $260 | $237.85 | +9.31% | 7 | Aug 5, 2024 | |
| RVTY Revvity | Maintains: Neutral | $118 → $127 | $111.34 | +14.07% | 1 | Jul 30, 2024 | |
| DHR Danaher | Maintains: Neutral | $270 → $275 | $233.10 | +17.98% | 3 | Jul 24, 2024 | |
| TXG 10x Genomics | Maintains: Neutral | $36 → $25 | $13.32 | +87.69% | 8 | Jul 18, 2024 | |
| BRKR Bruker | Maintains: Buy | $95 → $90 | $53.37 | +68.63% | 11 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $19.17 | +66.93% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $131.68 | -24.06% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $140 → $160 | $161.32 | -0.82% | 4 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $39 → $46 | $59.00 | -22.03% | 7 | Aug 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $86 | $78.04 | +10.20% | 11 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $35 | $18.27 | +91.57% | 3 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $5.30 | +145.28% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $390 → $405 | $311.66 | +29.95% | 6 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $350 → $315 | $357.77 | -11.95% | 11 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $88 | $52.70 | +66.98% | 5 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,650 → $1,525 | $1,166.90 | +30.69% | 9 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $17 | $15.36 | +10.68% | 3 | Apr 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $2.29 | +183.84% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $203.67 | +27.66% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $6.36 | +1,786.79% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $61 | $42.09 | +44.38% | 5 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $145 → $156 | $194.38 | -19.74% | 2 | Jul 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $16 → $13 | $15.30 | -15.03% | 11 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $175.67 | -31.69% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $3.11 | +189.39% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $418.61 | -43.86% | 3 | Nov 2, 2018 |
Charles River Laboratories International
Oct 2, 2024
Downgrades: Neutral
Price Target: $250 → $215
Current: $187.90
Upside: +14.42%
Thermo Fisher
Sep 16, 2024
Maintains: Buy
Price Target: $600 → $675
Current: $512.84
Upside: +31.62%
Phibro Animal Health
Aug 30, 2024
Maintains: Underperform
Price Target: $13 → $15
Current: $23.39
Upside: -35.87%
Agilent Technologies
Aug 22, 2024
Maintains: Neutral
Price Target: $140 → $147
Current: $128.57
Upside: +14.33%
Fortrea Holdings
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $19.15
Upside: +9.66%
Labcorp Holdings
Aug 5, 2024
Maintains: Buy
Price Target: $240 → $260
Current: $237.85
Upside: +9.31%
Revvity
Jul 30, 2024
Maintains: Neutral
Price Target: $118 → $127
Current: $111.34
Upside: +14.07%
Danaher
Jul 24, 2024
Maintains: Neutral
Price Target: $270 → $275
Current: $233.10
Upside: +17.98%
10x Genomics
Jul 18, 2024
Maintains: Neutral
Price Target: $36 → $25
Current: $13.32
Upside: +87.69%
Bruker
May 20, 2024
Maintains: Buy
Price Target: $95 → $90
Current: $53.37
Upside: +68.63%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $19.17
Upside: +66.93%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $131.68
Upside: -24.06%
Dec 12, 2023
Upgrades: Buy
Price Target: $140 → $160
Current: $161.32
Upside: -0.82%
Aug 31, 2023
Maintains: Underperform
Price Target: $39 → $46
Current: $59.00
Upside: -22.03%
Aug 1, 2023
Maintains: Neutral
Price Target: $94 → $86
Current: $78.04
Upside: +10.20%
Jun 16, 2023
Maintains: Buy
Price Target: $32 → $35
Current: $18.27
Upside: +91.57%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $5.30
Upside: +145.28%
Jun 16, 2023
Upgrades: Buy
Price Target: $390 → $405
Current: $311.66
Upside: +29.95%
May 10, 2023
Maintains: Neutral
Price Target: $350 → $315
Current: $357.77
Upside: -11.95%
May 10, 2023
Maintains: Buy
Price Target: $80 → $88
Current: $52.70
Upside: +66.98%
May 8, 2023
Maintains: Neutral
Price Target: $1,650 → $1,525
Current: $1,166.90
Upside: +30.69%
Apr 11, 2023
Maintains: Neutral
Price Target: $18 → $17
Current: $15.36
Upside: +10.68%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $2.29
Upside: +183.84%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $203.67
Upside: +27.66%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $6.36
Upside: +1,786.79%
Oct 6, 2020
Upgrades: Buy
Price Target: $61
Current: $42.09
Upside: +44.38%
Jul 7, 2020
Maintains: Buy
Price Target: $145 → $156
Current: $194.38
Upside: -19.74%
Apr 2, 2020
Reiterates: Underperform
Price Target: $16 → $13
Current: $15.30
Upside: -15.03%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $175.67
Upside: -31.69%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $3.11
Upside: +189.39%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $418.61
Upside: -43.86%